Texas Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 6.31 Cr
as on 16-11-2024
- Paid Up Capital ₹ 4.94 Cr
as on 16-11-2024
- Company Age 7 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -6.91%
(FY 2023)
- Profit -0.86%
(FY 2023)
- Ebitda 3.82%
(FY 2023)
- Net Worth 18.07%
(FY 2023)
- Total Assets 14.75%
(FY 2023)
About Texas Lifesciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 6.31 Cr and a paid-up capital of Rs 4.94 Cr, as per Ministry of Corporate Affairs (MCA) records.
Nina Gandhi, Rajiv Gandhi, Paragkumar Bhavsar, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24304GJ2017PTC097758
- Company No.
097758
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Jun 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Texas Lifesciences?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajiv Gandhi  | Director | 06-Jun-2017 | Current |
| Priya Gandhi | Director | 27-Jul-2020 | Current |
| Nina Gandhi | Director | 06-Jun-2017 | Current |
| Paragkumar Bhavsar | Director | 06-Jun-2017 | Current |
| Kamleshkumar Patel | Director | 06-Jun-2017 | Current |
Financial Performance of Texas Lifesciences.
Texas Lifesciences Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 6.91% decrease. The company also saw a slight decrease in profitability, with a 0.86% decrease in profit. The company's net worth Soared by an impressive increase of 18.07%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Texas Lifesciences?
In 2023, Texas Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Hester Diagnostics Private LimitedActive 26 years 7 monthsNina Gandhi and Rajiv Gandhi are mutual person
Blue Ray Aviation Private LimitedActive 15 years 4 monthsRajiv Gandhi and Priya Gandhi are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Texas Lifesciences?
Texas Lifesciences has a workforce of 46 employees as of Jul 24, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Texas Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Texas Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
